MedDataX Logo

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

NCT ID: NCT01025479

Last Updated: 2010-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

829 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Osteoporosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Osteoporosis Prostate cancer LHRH agonist and/or anti-androgen agent Korean prostate cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pathologic confirmation of prostate cancer
* patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria

* patients who are hard to be analysed by limitation of chart record according to investigators'discretion
* patients who already have been registered in this study
Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca MCMD

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joon Woo Bahn, MD

Role: STUDY_DIRECTOR

AstraZeneca Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Cheonan-si, Chungcheongnam-do, South Korea

Site Status

Research Site

Gangneung-si, Gangwon-do, South Korea

Site Status

Research Site

Goyang-si, Gyeonggi-do, South Korea

Site Status

Research Site

Guri-si, Gyeonggi-do, South Korea

Site Status

Research Site

Gumi, Gyeongsangbuk-do, South Korea

Site Status

Research Site

Gyeongju, Gyeongsangbuk-do, South Korea

Site Status

Research Site

Masan-si, Gyeongsangnam-do, South Korea

Site Status

Research Site

Iksan-si, Jeollabuk-do, South Korea

Site Status

Research Site

Cheongju-si, North Chungcheong, South Korea

Site Status

Research Site

Chungju, North Chungcheong, South Korea

Site Status

Research Site

Daegu, , South Korea

Site Status

Research Site

Daejeon, , South Korea

Site Status

Research Site

Gwangju, , South Korea

Site Status

Research Site

Incheon, , South Korea

Site Status

Research Site

Jeju City, , South Korea

Site Status

Research Site

Pusan, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Ulsan, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-OKR-CAS-2009/1

Identifier Type: -

Identifier Source: org_study_id